drugset / Trial / NCT00663832
A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
This Phase Ib dose escalation study is designed to characterize the safety, tolerability and preliminary efficacy of i.v. panobinostat (LBH589) in combination with docetaxel and prednisone in the 1st line treatment of patients with hormone refractory prostate cancer.
Timeline
- Start
- 2008-02
- Primary completion
- 2011-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | 10 mg/m2 | Intravenous |
| Subject | Panobinostat | Small molecule | 15 mg/m2 | Intravenous |
| Subject | Panobinostat | Small molecule | 20 mg/m2 | Intravenous |
| Background | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |